New drug may replace harsh chemo before transplant for hodgkin lymphoma patients
NCT ID NCT01508312
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 30 times
Summary
This study tested whether a targeted drug called brentuximab vedotin (SGN-35) could replace the standard ICE chemotherapy before a stem cell transplant for people with Hodgkin lymphoma that came back or didn't go away. 66 patients received two cycles of SGN-35, and PET scans were used to see if they still needed more chemo. The goal was to see if a less toxic approach could still lead to a successful transplant and long-term disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.